Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings South Africa Generic Drugs

Adcock Remains Resilient In Tough Business Environment

Firm Has Discontinued Three Generic Products This Year

  • News

Executive Summary

Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.

You may also be interested in...



Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.

Generics Industry Preps For Potential Entry Of Ukraine Into EU

Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings South Africa Generic Drugs
Latest Headlines

Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’

Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

See All
UsernamePublicRestriction

Register

GB152977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By